The risk of cytomegalovirus recurrence after kidney transplantation

Transplant International

Volumn 24, Issue 12, 2011, Pages 1170-1178

  Helanterä, Ilkka ^a   Lautenschlager, Irmeli ^a   Koskinen, Petri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

cytomegalovirus; kidney transplantation; recurrent infection

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; FEMALE; HUMAN; INFECTION RISK; KIDNEY TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RECURRENT DISEASE; VIRUS LOAD;

ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DELAYED GRAFT FUNCTION; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS; VIRAL LOAD;

EID: 80755135410     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01321.x     Document Type: Article

References (26)

1. Helanterä I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH,. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24: 339.
2. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166.
3. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
4. Helanterä I, Kyllonen L, Lautenschlager I, Salmela K, Koskinen P,. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant 2010; 10: 2026.
5. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
6. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731.
7. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
8. Ã-sberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
9. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV,. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717.
10. Ã-sberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205.
11. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A,. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94.
12. Humar A, Kumar D, Boivin G, Caliendo AM,. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829.
13. Muheim C, Vogel G, Seydoux C, et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 2002; 74: 226.
14. Helanterä I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19: 893.
15. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
16. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
17. Piiparinen H, Höckerstedt K, Grönhagen-Riska C, Lautenschlager I,. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30: 258.
18. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305.
19. Helanterä I, Lautenschlager I, Koskinen P,. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009; 24: 316.
20. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR,. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373.
21. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
22. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV,. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85.
23. Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010; 202: 585.
24. Manuel O, Pascual M, Trendelenburg M, Meylan PR,. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83: 359.
25. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214.
26. Ã-sberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010; 10: 1881.